Posts

Best Natural Alternatives to Mounjaro: What Actually Works for Weight Loss in 2026?

Image
Can you get some of the benefits of Mounjaro naturally? There is increasing interest in foods, dietary strategies and supplements that may reduce appetite, improve insulin sensitivity, increase satiety and support fat loss without using a prescription GLP-1/GIP medication. The important distinction is that there is no proven natural supplement that is equivalent to Mounjaro (tirzepatide) . Tirzepatide is a pharmacological dual GIP and GLP-1 receptor agonist. It produces substantially larger average weight loss than any individual food, supplement or lifestyle technique currently supported by human evidence. That does not make natural strategies irrelevant. For people who do not want medication, cannot tolerate it, or simply want to improve metabolic health alongside medical treatment, a more useful question is: Which natural interventions have the best evidence for reducing hunger, improving metabolic health, supporting fat loss and preserving muscle? This article re...

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: August 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection indic...